	US 12,070,484 B2
	Teverelix-TFA composition
Guy Poland, Bristol (GB); and Francois Boutignon, Clermont-Ferrand (FR)
Assigned to Antev Limited, London (GB)
Filed by Antev Limited, London (GB)
Filed on May 10, 2022, as Appl. No. 17/740,743.
Application 17/740,743 is a continuation of application No. 17/254,864, granted, now 11,357,818, previously published as PCT/EP2019/067728, filed on Jul. 2, 2019.
Claims priority of application No. 18181945 (EP), filed on Jul. 5, 2018.
Prior Publication US 2022/0273758 A1, Sep. 1, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/09 (2006.01); A61K 9/08 (2006.01); A61K 47/12 (2006.01); A61P 5/00 (2006.01); A61P 13/00 (2006.01); A61P 35/00 (2006.01)

CPC A61K 38/09 (2013.01) [A61K 9/08 (2013.01); A61K 47/12 (2013.01)]

14 Claims

1. A homogeneous teverelix-trifluoroacetate (TFA) composition having a molar ratio of teverelix (Ac-D-Nal-D-pClPhe-D-Pal-Ser-Tyr-D-Hci-Leu-Lys(iPr)-Pro-D-Ala-NH₂) to trifluoroacetate of at least 1:2.2 and at or below 1:2.8, such that for each mole of teverelix in the composition, the composition comprises at least 2.2 mol of trifluoroacetate and at or below 2.8 mol of trifluoroacetate, wherein peak plasma concentration (C_max) of teverelix after administration of the teverelix-TFA composition is stable relative to a teverelix-TFA composition having a molar ratio of teverelix to trifluoroacetate of below 1:2.2.